PMID- 19063817
OWN - NLM
STAT- MEDLINE
DCOM- 20090514
LR  - 20161020
IS  - 1088-5412 (Print)
IS  - 1088-5412 (Linking)
VI  - 30
IP  - 1
DP  - 2009 Jan-Feb
TI  - Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in Turkish children 
      with asthma and allergic rhinitis.
PG  - 41-6
LID - 10.2500/aap.2009.30.3183 [doi]
AB  - Plasminogen activator inhibitor (PAI-1) has an essential role in tissue 
      remodeling after inflammation. Recent literature revealed only one study 
      evaluating PAI-1 4G/5G gene polymorphism in children with asthma and none in 
      children with allergic rhinitis. We aimed to investigate distribution of PAI-1 
      4G/5G polymorphism in a group of Turkish children with asthma and allergic 
      rhinitis and compare these findings with those obtained in normal peers. Patients 
      with physician-diagnosed asthma (n = 106) and allergic rhinitis (n = 99) and 83 
      healthy peers were included in this study. We evaluated PAI-1 4G/5G polymorphism 
      genotype as well as the possible association between PAI-1 4G/5G polymorphism and 
      pulmonary function tests, serum total immunoglobulin E (IgE), total eosinophil 
      count, and skin-prick test positivity in our study. The prevalence of the 4G 
      allele significantly exceeded the values found in the controls both in patients 
      with asthma (p = 0.001) and in patients with allergic rhinitis (p = 0.002). 
      Interestingly, comparison of asthmatic patients revealed that mean baseline 
      percent forced expiratory volume in 1 second and forced vital capacity were 
      significantly higher in patients who bear 5G/5G genotype than in those who have 
      4G/4G or 4G/5G genotypes. No statistically significant relationship were found 
      between PAI-1 polymorphism and total serum IgE levels, total eosinophil count, or 
      selected skin test responses to aeroallergens. Our study suggests that Turkish 
      children with asthma or allergic rhinitis have a higher prevalence of PAI-1 4G 
      allele compared with their healthy peers.
FAU - Ozbek, Ozlem Yilmaz
AU  - Ozbek OY
AD  - Department of Pediatric Allergy, Baskent University Faculty of Medicine, Ankara, 
      Turkey. ozlemozbek@superonline.com
FAU - Atac, F Belgin
AU  - Atac FB
FAU - Ogus, Ersin
AU  - Ogus E
FAU - Ozbek, Namik
AU  - Ozbek N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081206
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Plasminogen Activator Inhibitor 1)
RN  - 0 (SERPINE1 protein, human)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adolescent
MH  - Asthma/epidemiology/*genetics
MH  - Cell Count
MH  - Child
MH  - Eosinophils/immunology/pathology
MH  - Female
MH  - Gene Frequency
MH  - *Genetic Predisposition to Disease
MH  - Genotype
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Male
MH  - Plasminogen Activator Inhibitor 1/*genetics/immunology/metabolism
MH  - *Polymorphism, Genetic
MH  - Respiratory Function Tests
MH  - Rhinitis, Allergic, Perennial/epidemiology/*genetics
MH  - Rhinitis, Allergic, Seasonal/epidemiology/*genetics
MH  - Skin Tests
MH  - Turkey
EDAT- 2008/12/10 09:00
MHDA- 2009/05/15 09:00
CRDT- 2008/12/10 09:00
PHST- 2008/12/10 09:00 [pubmed]
PHST- 2009/05/15 09:00 [medline]
PHST- 2008/12/10 09:00 [entrez]
AID - 3183 [pii]
AID - 10.2500/aap.2009.30.3183 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2009 Jan-Feb;30(1):41-6. doi: 10.2500/aap.2009.30.3183. Epub 
      2008 Dec 6.